{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:36Z","timestamp":1780121016264,"version":"3.54.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015926","name":"David and June Trone Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.pbb.2025.174087","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:25:35Z","timestamp":1755807935000},"page":"174087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives"],"prefix":"10.1016","volume":"256","author":[{"given":"Shadan","family":"Rahmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Crupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: A nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0010","first-page":"223","article-title":"A review of LSD treatment in alcoholism","volume":"6","author":"Abuzzahab","year":"1971","journal-title":"Int. Pharmacopsychiatry."},{"issue":"8","key":"10.1016\/j.pbb.2025.174087_bb0015","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00213-024-06620-x","article-title":"Psychedelic-assisted psychotherapy: where is the psychotherapy research?","volume":"241","author":"Aday","year":"2024","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.pbb.2025.174087_bb0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: safety and ethical concerns","volume":"7","author":"Anderson","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.pbb.2025.174087_bb0025","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1176\/appi.ps.20220204","article-title":"Excited delirium, ketamine, and deaths in police custody","volume":"vol. 73","author":"Appelbaum","year":"2022","journal-title":"Psychiatric Services"},{"issue":"7929","key":"10.1016\/j.pbb.2025.174087_bb0030","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1038\/d41586-022-02875-6","article-title":"Psychedelic research and the real world","volume":"609","author":"Appelbaum","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamapsychiatry.2024.0124","article-title":"Informed consent to psychedelic treatment-a work in progress","volume":"81","author":"Appelbaum","year":"2024","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.pbb.2025.174087_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111461","article-title":"An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: insights, limitations and future directions","author":"Askariyan","year":"2025","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174087_bb0045","article-title":"Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine","author":"Avram","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"14","key":"10.1016\/j.pbb.2025.174087_bb0050","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1021\/acschemneuro.4c00245","article-title":"Acute effects of hallucinogens on functional connectivity: psilocybin and salvinorin-A","volume":"15","author":"Bagdasarian","year":"2024","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/02791072.2019.1593560","article-title":"Effects of the psychedelic amphetamine MDA (3,4-Methylenedioxyamphetamine) in healthy volunteers","volume":"51","author":"Baggott","year":"2019","journal-title":"J. Psychoactive Drugs"},{"issue":"12","key":"10.1016\/j.pbb.2025.174087_bb0060","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1091\/mbc.E20-05-0340","article-title":"Catalysts for change: the cellular neurobiology of psychedelics","volume":"32","author":"Banks","year":"2021","journal-title":"Mol. Biol. Cell"},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb0065","article-title":"American psychiatrists\u2019 opinions about classic hallucinogens and their potential therapeutic applications: a 7-year follow-up survey","volume":"1","author":"Barnett","year":"2024","journal-title":"Psychedelic Medicine"},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0070","article-title":"Funding success of United States federal grant applications proposing to study therapeutic applications of psychedelics: a survey study","volume":"4","author":"Barnett","year":"2025","journal-title":"Psychoactives"},{"key":"10.1016\/j.pbb.2025.174087_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103473","article-title":"United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006\u20132020","volume":"99","author":"Barnett","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.pbb.2025.174087_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109214","article-title":"Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines","volume":"219","author":"Belouin","year":"2022","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2025.174087_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"10","key":"10.1016\/j.pbb.2025.174087_bb0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.pbb.2025.174087_bb0095","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb5010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.pbb.2025.174087_bb0100","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of Oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pbb.2025.174087_bb0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2017.11.028","article-title":"A regulatory perspective on the evaluation of hallucinogen drugs for human use","volume":"142","author":"Calderon","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2025.174087_bb5000","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/164_2018_107","article-title":"Serotonergic psychedelics: Experimental approaches for assessing mechanisms of action","volume":"252","author":"Canal","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2025.174087_bb0110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb0115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174087_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted psychotherapy-A systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front. Psychol."},{"issue":"3","key":"10.1016\/j.pbb.2025.174087_bb0125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/17456916221120428","article-title":"Complex racial trauma: evidence, theory, assessment, and treatment","volume":"18","author":"C\u00e9nat","year":"2022","journal-title":"Perspect. Psychol. Sci."},{"issue":"8","key":"10.1016\/j.pbb.2025.174087_bb0130","doi-asserted-by":"crossref","DOI":"10.1213\/XAA.0000000000001613","article-title":"Anesthetic-induced intraoperative dream associated with remission of a psychiatric disorder: A case report","volume":"16","author":"Chow","year":"2022","journal-title":"A&A Practice"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/15265161.2025.2434398","article-title":"Psychedelic medicine exceptionalism","volume":"25","author":"Cohen","year":"2025","journal-title":"The American Journal of Bioethics\u00a0: AJOB"},{"issue":"5","key":"10.1016\/j.pbb.2025.174087_bb0140","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.pbb.2025.174087_bb0145","first-page":"1","article-title":"Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color","volume":"3","author":"Davis","year":"2021","journal-title":"Chronic Stress"},{"key":"10.1016\/j.pbb.2025.174087_bb0150","author":"Deloite"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance","volume":"49","author":"Dinis-Oliveira","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.pbb.2025.174087_bb0160","series-title":"History & Current Status of the Psychedelic Field. American University Symposium on the Therapeutic Use of Psychedelic","author":"Doblin","year":"2024"},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/02791072.2019.1606472","article-title":"The past and future of psychedelic science: an introduction to this issue","volume":"51","author":"Doblin","year":"2019","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pbb.2025.174087_bb0170","series-title":"Drugs of Abuse, A DEA Resource Guide (2020 Edition)","author":"Doj","year":"2020"},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb0175","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/brain\/awab406","article-title":"Models of psychedelic drug action: modulation of cortical-subcortical circuits","volume":"145","author":"Doss","year":"2022","journal-title":"Brain J. Neurol."},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/15265161.2020.1861364","article-title":"Racial justice requires ending the war on drugs","volume":"21","author":"Earp","year":"2021","journal-title":"Am. J. Bioeth."},{"key":"10.1016\/j.pbb.2025.174087_bb0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1176\/appi.prcp.20240128","article-title":"On minimizing risk and harm in the use of psychedelics","volume":"7","author":"Evans","year":"2025","journal-title":"Psychiatric Research and Clinical Practice"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/wps.21067","article-title":"Clinical trials of novel psychotropic agents: some caveats","volume":"22","author":"Fischer","year":"2023","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.pbb.2025.174087_bb0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1037\/pha0000490","article-title":"Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies","volume":"29","author":"Fogg","year":"2021","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.20241025","article-title":"Psychedelics in psychiatry: oh, what A trip!","volume":"182","author":"Fonzo","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/appi.ajp.20230682","article-title":"Psilocybin: from psychiatric Pariah to perceived panacea","volume":"182","author":"Fonzo","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2025.174087_bb0210","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia-Romeu","year":"2019","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"3","key":"10.1016\/j.pbb.2025.174087_bb0215","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","article-title":"Default mode network modulation by psychedelics: A systematic review","volume":"26","author":"Gattuso","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2025.174087_bb0220","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s11013-021-09749-y","article-title":"Ancient roots of today\u2019s emerging renaissance in psychedelic medicine","volume":"46","author":"George","year":"2022","journal-title":"Cult. Med. Psychiatry"},{"issue":"5","key":"10.1016\/j.pbb.2025.174087_bb0225","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.bpsc.2023.11.003","article-title":"A brief historical overview of psychedelic research","volume":"9","author":"Geyer","year":"2024","journal-title":"Biological Psychiatry. Cognitive Neuroscience and Neuroimaging"},{"issue":"5","key":"10.1016\/j.pbb.2025.174087_bb5005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tics.2023.01.003","article-title":"A complex systems perspective on psychedelic brain action","volume":"27","author":"Girn","year":"2023","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.pbb.2025.174087_bb0230","article-title":"Inside the movement to decolonize psychedelic pharma","author":"Gregoire","year":"2021","journal-title":"ProtoLife"},{"issue":"12","key":"10.1016\/j.pbb.2025.174087_bb0235","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pbb.2025.174087_bb0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Online first pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"58","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.pbb.2025.174087_bb0245","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan","year":"2023","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0250","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1176\/appi.ajp.20230698","article-title":"Reduction in trauma-related symptoms after anesthetic-induced intra-operative dreaming","volume":"181","author":"Hack","year":"2024","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.pbb.2025.174087_bb0255","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamapsychiatry.2021.2329","article-title":"Applying anti-racism to clinical care and research","volume":"78","author":"Haeny","year":"2021","journal-title":"JAMA Psychiat."},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/S0033291721004207","article-title":"Why was early therapeutic research on psychedelic drugs abandoned?","volume":"52","author":"Hall","year":"2022","journal-title":"Psychol. Med."},{"issue":"7969","key":"10.1016\/j.pbb.2025.174087_bb0265","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-02093-8","article-title":"Australia to prescribe MDMA and psilocybin for PTSD and depression in world first","volume":"619","author":"Haridy","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/15265161.2024.2433423","article-title":"Wolves among sheep: sexual violations in psychedelic-assisted therapy","volume":"25","author":"Harrison","year":"2025","journal-title":"The American Journal of Bioethics\u00a0: AJOB"},{"issue":"522","key":"10.1016\/j.pbb.2025.174087_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw6435","article-title":"Distinct neural mechanisms for the prosocial and rewarding properties of MDMA","volume":"11","author":"Heifets","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.pbb.2025.174087_bb0280","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1152\/physrev.00033.2019","article-title":"Revisiting the functional anatomy of the human brain: toward a Meta-networking theory of cerebral functions","volume":"100","author":"Herbet","year":"2020","journal-title":"Physiol. Rev."},{"issue":"NOV","key":"10.1016\/j.pbb.2025.174087_bb0285","article-title":"The human brain in numbers: a linearly scaled-up primate brain","volume":"3","author":"Herculano-Houzel","year":"2009","journal-title":"Front. Hum. Neurosci."},{"issue":"7","key":"10.1016\/j.pbb.2025.174087_bb0290","doi-asserted-by":"crossref","first-page":"2524119","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression a meta-analysis + supplemental content","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.pbb.2025.174087_bb0295","series-title":"Overpatented, Overpriced","author":"I-Mak.","year":"2022"},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb4020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/acsptsci.0c00198","article-title":"Consciousness, religion, and gurus: Pitfalls of psychedelic medicine","volume":"4","author":"Johnson","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0300","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"11","key":"10.1016\/j.pbb.2025.174087_bb0305","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pbb.2025.174087_bb0310","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.pbb.2025.174087_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049470","article-title":"Polymorphs and prodrugs and salts (oh my!): an empirical analysis of \u201c\u2018secondary\u2019\u201d Pharmaceutical Patents","volume":"7","author":"Kapczynski","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2025.174087_bb0320","author":"Kilmer"},{"key":"10.1016\/j.pbb.2025.174087_bb0325","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-med-051322-120608","article-title":"Ketamine: mechanisms and relevance to treatment of depression","volume":"75","author":"Kim","year":"2024","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0330","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1353\/pbm.2024.a919716","article-title":"Are psychedelic experiences transformative? Can we consent to them?","volume":"67","author":"Kious","year":"2024","journal-title":"Perspect. Biol. Med."},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0335","first-page":"161","article-title":"Hallucinogenic plants in Chinese herbals","volume":"25","author":"Li","year":"1977","journal-title":"Bot. Mus. Leafl. Harv. Univ."},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0340","article-title":"The claustrum and consciousness: an update","volume":"23","author":"Liaw","year":"2023","journal-title":"International Journal of Clinical and Health Psychology\u00a0: IJCHP"},{"issue":"11","key":"10.1016\/j.pbb.2025.174087_bb0345","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nature. Mental Health"},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb0350","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-4347(98)00067-X","article-title":"Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction","volume":"709","author":"Lindenblatt","year":"1998","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.pbb.2025.174087_bb4010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111129","article-title":"Classic psychedelics and the treatment for alcoholism","volume":"135","author":"Lodetti","year":"2024","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/02698811221140011","article-title":"A unified model of ketamine\u2019s dissociative and psychedelic properties","volume":"37","author":"Marguilho","year":"2023","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pbb.2025.174087_bb0360","article-title":"Ayahuasca for the treatment of alcohol use disorder","volume":"178","author":"Marinho","year":"2024","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.pbb.2025.174087_bb0365","article-title":"Patents on psychedelics: the next legal battlefront of drug development. Harvard law review","volume":"135","author":"Marks","year":"2021","journal-title":"Forum"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0370","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamapsychiatry.2024.0184","article-title":"Essentials of informed consent to psychedelic medicine","volume":"81","author":"Marks","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2025.174087_bb0375","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/02698811241232548","article-title":"Psychiatric risks for worsened mental health after psychedelic use","volume":"38","author":"Marrocu","year":"2024","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0380","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"McClure-Begley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.pbb.2025.174087_bb4000","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"issue":"6643","key":"10.1016\/j.pbb.2025.174087_bb0385","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1126\/science.adg1324","article-title":"Pressing regulatory challenges for psychedelic medicine","volume":"380","author":"McGuire","year":"2023","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0390","doi-asserted-by":"crossref","first-page":"E2414650","DOI":"10.1001\/jamanetworkopen.2024.14650","article-title":"Developing an ethics and policy framework for psychedelic clinical care: A consensus statement","volume":"7","author":"McGuire","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004540","article-title":"Predicting patent challenges for small-molecule drugs: A cross-sectional study","volume":"22","author":"Memedovich","year":"2025","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0400","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0405","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41386-023-01656-7","article-title":"Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism","volume":"49","author":"Mitchell","year":"2024","journal-title":"Neuropsychopharmacology\u00a0: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0410","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.pbb.2025.174087_bb0415","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0420","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of AE3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2010","journal-title":"Journal of Psychophamacology"},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0425","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2025.174087_bb0430","doi-asserted-by":"crossref","first-page":"E204","DOI":"10.1503\/cmaj.241191","article-title":"Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population","volume":"197","author":"Myran","year":"2025","journal-title":"CMAJ Can. Med. Assoc. J."},{"issue":"3","key":"10.1016\/j.pbb.2025.174087_bb4015","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22r14518","article-title":"Control conditions in randomized trials of psychedelics: An ACTTION systematic review","volume":"84","author":"Nayak","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0435","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1310-3990","article-title":"The history of psychedelics in psychiatry","volume":"54","author":"Nichols","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0440","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41562-025-02103-x","article-title":"Shrinking the know-do gap in psychedelic-assisted therapy","volume":"9","author":"Nicol","year":"2025","journal-title":"Nat. Hum. Behav."},{"issue":"7","key":"10.1016\/j.pbb.2025.174087_bb0445","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts","volume":"32","author":"Noorani","year":"2018","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pbb.2025.174087_bb0450","author":"Oregon Health Authority"},{"key":"10.1016\/j.pbb.2025.174087_bb0455","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40262-024-01454-4","article-title":"Clinical pharmacokinetics of psilocin after psilocybin administration: A systematic review and post-hoc analysis","volume":"64","author":"Otto","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0460","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.pbb.2025.174087_bb0465","article-title":"5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA","author":"Pomrenze","year":"2024","journal-title":"BioRxiv: The Preprint Server for Biology."},{"key":"10.1016\/j.pbb.2025.174087_bb0470","series-title":"Psychedelic Alpha","author":"Psychedelic Legalization & Decriminalization Tracker","year":"2025"},{"key":"10.1016\/j.pbb.2025.174087_bb0475","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-neuro-071013-014030","article-title":"The brain\u2019s default mode network","volume":"38","author":"Raichle","year":"2015","journal-title":"Annu. Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.pbb.2025.174087_bb0480","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2025.174087_bb0485","series-title":"Do the therapeutic effects of Psilocybin involve actions in the gut?","author":"Reed","year":"2023"},{"issue":"5","key":"10.1016\/j.pbb.2025.174087_bb0490","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174087_bb0495","series-title":"Translational Neuroscience: Toward New Therapies [Internet]","article-title":"From rodent behavioral models to human disorders","author":"Robbins","year":"2015"},{"issue":"12","key":"10.1016\/j.pbb.2025.174087_bb0500","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0505","first-page":"1","article-title":"Today's pirates: biopiracy, biotech, and the international frameworks that are not up to the challenge","volume":"15","author":"Rotzin","year":"2024","journal-title":"UC Law Sci. Technol. J."},{"issue":"14","key":"10.1016\/j.pbb.2025.174087_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26146673","article-title":"The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for treatment-resistant depression: the convergence of molecular and psychological treatment","volume":"26","author":"Sakopoulos","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0515","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"10","key":"10.1016\/j.pbb.2025.174087_bb0520","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.biopsych.2024.02.132","article-title":"Psilocybin desynchronizes brain networks","volume":"95","author":"Siegel","year":"2024","journal-title":"Biol. Psychiatry"},{"issue":"8023","key":"10.1016\/j.pbb.2025.174087_bb0525","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","article-title":"Psilocybin desynchronizes the human brain","volume":"632","author":"Siegel","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2025.174087_bb0530","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41386-023-01710-4","article-title":"Ensuring psychedelic treatments and research do not leave anyone behind","volume":"49","author":"Simon","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41591-023-02727-4","article-title":"The safety of supported psilocybin use in Oregon","volume":"30","author":"Smith","year":"2024","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0540","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00213-024-06598-6","article-title":"In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials","volume":"241","author":"Soliman","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2025.174087_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0327778","article-title":"MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: systematic literature review","author":"Stanicic","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2025.174087_bb0550","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s13181-023-00944-4","article-title":"ACMT Position Statement: End the Use of the Term \u201cExcited Delirium.\u201d","volume":"19","author":"Stolbach","year":"2023","journal-title":"J. Med. Toxicol."},{"issue":"11","key":"10.1016\/j.pbb.2025.174087_bb0555","article-title":"Research abuses against people of colour and other vulnerable groups in early psychedelic research","volume":"42","author":"Strauss","year":"2021","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.pbb.2025.174087_bb0560","author":"The Business Research Company"},{"key":"10.1016\/j.pbb.2025.174087_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1391689","article-title":"In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin","volume":"15","author":"Thomann","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2025.174087_bb0570","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/da.22217","article-title":"Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV","volume":"31","author":"Uher","year":"2014","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2025.174087_bb0575","author":"United States Drug Enforcement Administration"},{"key":"10.1016\/j.pbb.2025.174087_bb0580","author":"United States Patent and Trademark Office"},{"key":"10.1016\/j.pbb.2025.174087_bb0585","doi-asserted-by":"crossref","DOI":"10.1017\/S0963180124000604","article-title":"How to make psychedelic-assisted therapy safer","author":"Villiger","year":"2024","journal-title":"Cambridge Quarterly of Healthcare Ethics: CQ: The International Journal of Healthcare Ethics Committees"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0590","doi-asserted-by":"crossref","first-page":"2","DOI":"10.9758\/cpn.23.1120","article-title":"Psilocybin, an effective treatment for major depressive disorder in adults - A systematic review","volume":"22","author":"Watford","year":"2024","journal-title":"Clinical Psychopharmacology and Neuroscience: The Official Scientific Journal of the Korean College of Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2025.174087_bb0595","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cbpra.2022.07.001","article-title":"An evidence-based approach for treating stress and trauma due to racism","volume":"30","author":"Williams","year":"2023","journal-title":"Cogn. Behav. Pract."},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0600","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/appi.ajp.20230681","article-title":"MDMA and MDMA-assisted therapy","volume":"182","author":"Wolfgang","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2025.174087_bb0605","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1176\/appi.ajp.20240751","article-title":"Research and implementation of psychedelic-assisted therapy in the veterans health administration","volume":"182","author":"Wolfgang","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2025.174087_bb0610","doi-asserted-by":"crossref","first-page":"1386321","DOI":"10.3389\/fpsyt.2024.1386321","article-title":"Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Psych."},{"issue":"2","key":"10.1016\/j.pbb.2025.174087_bb4005","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"34","key":"10.1016\/j.pbb.2025.174087_bb0615","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101743118","article-title":"Parallel hippocampal-parietal circuits for self- and goal-oriented processing","volume":"118","author":"Zheng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725001340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305725001340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:58:53Z","timestamp":1780120733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305725001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":131,"alternative-id":["S0091305725001340"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2025.174087","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2025.174087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"174087"}}